A Long Noncoding RNA, GAS5 Can Be a Biomarker for Docetaxel Response in Castration Resistant Prostate Cancer
While functional studies of long noncoding RNAs (lncRNAs) have mostly focused on how they influence disease diagnosis and prognosis, the pharmacogenomic relevance of lncRNAs remains largely unknown. Here, we test the hypothesis that the expression of a lncRNA, grow arrest-specific 5 (GAS5) can be a...
Main Authors: | Yuting Shan, Yingbo Huang, Adam M. Lee, Joshua Mentzer, Alexander Ling, R. Stephanie Huang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-05-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.675215/full |
Similar Items
-
CLINICAL ASSESSMENT OF TAXANES IN THE FIRST-LINE CYTOTOXIC THERAPY OF CASTRATION-RESISTANT PROSTATE CANCER
by: A. A. GRITSKEVICH, et al.
Published: (2016-12-01) -
Prediction for survival following docetaxel-based chemotherapy in Taiwanese men with castration-resistant metastatic prostate cancer
by: Kai-Fu Yang, et al.
Published: (2015-12-01) -
Identification of biomarkers, pathways and potential therapeutic target for docetaxel resistant prostate cancer
by: Rui-ji Liu, et al.
Published: (2021-01-01) -
A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer
by: Peng Gu, et al.
Published: (2019-06-01) -
Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients
by: N. K. Mazina, et al.
Published: (2017-11-01)